Sagent Pharmaceuticals, a provider of generic and specialty pharmaceuticals, has added travoprost ophthalmic solution, USP 0.004% to its portfolio of offerings. A prostaglandin analogue, travoprost is indicated to treat elevated intraocular pressure associated with open-angle glaucoma and hypertension. The drug represents a $61 million market in the past year, according to Sagent.

Travoprost is the first ophthalmic product offering in the company’s portfolio. In a press release, the company said it will be introducing additional ophthalmic products during the upcoming year. GP